Delos Capital

Activity from announced rounds

Activity in this selectionJan 31, 2026 · Jan 1, 2026
Rounds participated in
2
Confirmed lead rounds
—
2 roles undisclosed
New companies
2
First participation on record · 0 follow-on
Funding in participating rounds
$58M
2 disclosed · full round size, not this investor’s share

By stage

Seed1
Undisclosed1

By primary sector

Biotech2

By country

United States2

Rounds

2 in this selection
TRex Bio

Develops precision immunoregulatory medicines based on tissue Treg biology

$50MUndisclosed
Role not disclosed
STRM.BIO

Develops non-viral gene delivery platform for in vivo cell engineering and gene therapy

$8MSeed2
Role not disclosed